Log in
Enquire now
LabGenius

LabGenius

Synthetic biology company that uses AI, DNA synthesis, and robotics to discover biological molecules.

OverviewStructured DataIssuesContributors

Contents

labgeni.us
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Machine learning
Machine learning
Artificial Intelligence (AI)
Artificial Intelligence (AI)
Robotics
Robotics
Automation
Automation
Drug discovery
Drug discovery
...
Location
London
London
United Kingdom
United Kingdom
B2X
B2B
B2B
CEO
‌
James Field
Founder
‌
James Field
AngelList URL
angel.co/labgenius
Date Incorporated
2012
Number of Employees (Ranges)
51 – 2000
Email Address
didier.landais@labgeni.us?subject=LabGenius%20Partnerships&cc=cam.watson%40labgeni.us
partnerships@labgeni.us
Full Address
Suite 1, 3rd Floor 11-12 St. James's Square LONDON , SW1Y 4LB United Kingdom
CIK Number
1,718,254
Investors
Jude Gomila
Jude Gomila
Acequia Capital
Acequia Capital
Gigafund
Gigafund
Felicis Ventures
Felicis Ventures
Josh Manchester
Josh Manchester
Beast Ventures
Beast Ventures
0
Berggruen Holdings
Berggruen Holdings
Beast (venture capital)
Beast (venture capital)
0
...
Founded Date
2012
0
Total Funding Amount (USD)
101,400,000
Latest Funding Round Date
May 21, 2024
Glassdoor ID
2263427
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Wellfound ID
labgenius
Country
United Kingdom
United Kingdom
Headquarters
London
London

Other attributes

Blog
medium.com/@james_field
Company Operating Status
Active
Latest Funding Round Amount (USD)
44,000,000
Wikidata ID
Q56585160

LabGenius is a privately held, synthetic biology company based in London, UK. It uses a combination of artificial intelligence, DNA synthesis, and robotics to discover high-value biological molecules.

The company's novel technology is able to produce trillions of variations of gene sequences, which can be used to create new biological materials using artificial intelligence. It can predict which gene mutations will improve a biological design, thereby enabling scientists to produce new therapeutics or other materials such as adhesives, catalysts, and sensors.

LabGenius, in partnership with leading multinationals, is developing various products, focusing on the areas of biotherapeutics, advanced materials, and personal care. In the biotherapeutics category, LabGenius' AI-driven evolution engine, EVA, is learning how to optimally enhance the stability of therapeutic proteins in protease rich environments such as the GI tract, tumor microenvironments, and inflammed tissues. The end goal is to enable the delivery of novel therapies for unmet clinical needs.

In the advanced materials area, engineered proteins can be used to form high value coatings, adhesives, fibres, catalysts, and sensors. LabGenius has completed several development projects in this area and are engaged in collaborative development with aerospace and defence companies.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Contact us - LabGeni

https://www.labgeni.com/contact-us

Web

LabGenius Locks Down $3.66m From Top-Tier Investors To Harness Evolution - SynBioBeta

https://synbiobeta.com/labgenius-locks-3-66m-top-tier-investors-harness-evolution/

Web

References

Find more companies like LabGenius

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.